Aspira Women's Health awarded $10M ARPA-H grant for endometriosis blood test

Aspira Women's Health Inc.

Selected by ARPA-H for Sprint for Women's Health; $10M funding over two years to develop ENDOinform blood test for endometriosis.
First milestone expected Q4 2024; $2M payment upon successful acceptance.
One of only six Launchpad awards among 1,700+ submissions; among largest awards approved.
Virtual Investor Day scheduled for October 29, 2024 at 3:00 p.m. ET.
ENDOinform aims to replace laparoscopic surgery for diagnosing endometriosis, affecting 6M women in US.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.